Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
A recent study is raising new questions about whether cannabis-derived compounds could one day play a role in liver care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results